{"version":"1.0","type":"link","title":"Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.","author_name":"Taylor MH 외","author_url":"https://prs-insight.online/author/Taylor%20MH","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/146445","thumbnail_width":1200,"thumbnail_height":630}